Abstract: The compound [3S(Z)]-3-[[(2-amino-4-thiazolyl)[[2-(hydroxyamino)-2-oxoethoxy]imino]acet yl]amino]-2,2-dimethyl-4-oxo-1-azetidinyl sulfate has gram-positive and gram-negative activity and good oral absorption.

Abstract: This application relates to compounds of formula (I), which are useful as antihypercholesterolemic agents.

Abstract: Compounds having the formula ##STR1## and pharmaceutically acceptable salts thereof which possess antibacterial activity.R.sub.s is a substituted hydroxy pyridone of the formulae: ##STR2## wherein Y.sub.1 is CH.sub.2 X; COOR.sub.6 ; CONR.sub.7 R.sub.8 ; OH; OCH.sub.2 R.sub.9 ; CHF.sub.2 ; CHO; CH.dbd.N--OR.sub.10 ; CH.dbd.CH--R.sub.11 ; CN; CH.dbd.N--NHR.sub.12, and Y.sub.2 is hydrogen; COOH; CONH.sub.2 ; CN; CSNH.sub.2 ; COO lower alkyl; CONR.sub.7 /R.sub.8.

Abstract: The present invention relates to new 3-guanidinoalkyl-2-azetidinones of the formula ##STR1## wherein: U and W can be the same or different and are selected from the group consisting of hydrogen and an amino protecting group;n is 1 to 3;X is a member selected from the group consisting of hydrogen, trialkylsilyl, arylsulfonyl, amino substituted arylsulfonyl, alkylsulfonyl, arylaminocarbonyl, alkylcarbonyl and arylcarbonyl; andY is a member selected from the group consisting of hydrogen, arylalkenyl, arylalkyl, formyl, carboxy, alkoxycarbonyl, acyloxy, arylthio, arylsulfinyl, arylsulfonyl, alkylthio, alkylsulfinyl, alkylsulfonyl, arylaminocarbonyl, the radical ##STR2## in which R is hydrogen, alkyl or arylalkyl, and the radical ##STR3## in which m is 1 to 3 and R' is hydrogen or --CO.sub.2 R" wherein R" is hydrogen, alkyl or arylalkyl.The novel axetidinones of the present invention exhibit anti-thrombin and anti-trypsin activities and are thus useful in controlling blood coagulation and treating pancreatitis.

Abstract: 1-Carbapenam-2-one-3-carboxylic acid and 1-carba-3-hydroxy-3-cephem-4-carboxylic acid and esters thereof are provided by a process comprising a rhodium C.sub.2 -C.sub.10 carboxylate catalyzed cyclization of an ester of a 4-(1-alkoxy- or 1-substituted alkoxy)-2-oxo-4-azetidinyl)-.beta.-ketobutyric acid and an ester of a 5-(1-alkoxy- or 1-substituted alkoxy-2-oxo-4-azetidinyl)-.alpha.-diazo-.beta.-ketovaleric acid respectively. The process is carried out in an inert organic solvent at a temperature between about 15.degree. C. and about 85.degree. C. The 1-carba bicyclic .beta.-lactams are intermediates for preparing antibiotics.

Abstract: Novel syn isomers of reacemates and optical isomers of 3-amino-2-oxo-azetidine-1-sulfonic acids of the formula ##STR1## wherein R is difluoromethyl, R.sub.1 is --(CH.sub.2).sub.n --X, n is an integer from 1 to 4, X is selected from the group consisting of halogen, --CN, --OR.sub.1 ', --SR.sub.1 ", azido, thiocyanate, isothiocyanate, and ##STR2## R.sub.1 ' is selected from the group consisting of hydrogen and alkyl of 1 to 4 carbon atoms, R.sub.1 " is selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms and a heterocycle and R' and R" are individually selected from the group consisting of hydrogen and alkyl of 1 to 4 carbon atoms and taken together with the nitrogen to which they are attached form a heterocycle and A.sup.1 is selected from the group consisting of hydrogen, and metal cations and their nontoxic, pharmaceutically acceptable acid addition salts, the wavy line indicating the cis form, trans form or cis trans forms having antibiotic properties.

Abstract: 1-Carbapenam-2-one-3-carboxylic acid and 1-carba-3-hydroxy-3-cephem-4-carboxylic acid and esters thereof are provided by a process comprising a rhodium C.sub.2 -C.sub.10 carboxylate catalyzed cyclization of an ester of a 4-(1-alkoxy- or 1-substituted alkxoy)-2-oxo-4-azetidinyl)-.alpha.-diazo-.beta.-ketobutyric acid and an ester of a 5-(1-alkoxy- or 1-substituted alkoxy-2-oxo-4-azetidinyl)-.alpha.-diazo-.beta.-ketovaleric acid respectively. The process is carried out in an inert organic solvent at a temperature between about 15.degree. C. and about 85.degree.0 C. The 1-carba bicyclic .beta.-lactams are intermediates for preparing antibiotics.

Abstract: The present invention relates to new 3-guanidinoalkyl-2-azetidinones of the formula ##STR1## wherein: U and W can be the same or different and are selected from the group consisting of hydrogen and an amino protecting group;n is 1 to 3;X is a member selected from the group consisting of hydrogen, trialkylsilyl, arylsulfonyl, amino substituted arylsulfonyl, alkylsulfonyl, arylaminocarbonyl, alkylcarbonyl and arylcarbonyl; andY is a member selected from the group consisting of hydrogen, arylalkenyl, arylalkyl, formyl, carboxy, alkoxycarbonyl, acyloxy, arylthio, arylsulfinyl, arylsulfonyl, alkylthio, alkylsulfinyl, alkylsulfonyl, arylaminocarbonyl, the radical ##STR2## in which R is hydrogen, alkyl or arylalkyl, and the radical ##STR3## in which m is 1 to 3 and R' is hydrogen or --CO.sub.2 R" wherein R" is hydrogen, alkyl or arylalkyl.The novel azetidinones of the present invention exhibit anti-thrombin and anti-trypsin activities and are thus useful in controlling blood coagulation and treating pancreatitis.

Abstract: Antibacterial activity is exhibited by novel compounds having the formula ##STR1## or a pharmaceutically acceptable salt thereof. R.sub.3 and R.sub.4 are the same or different and each is hydrogen or alkyl or R.sub.3 and R.sub.4 taken together with the nitrogen atoms to which they are attached form a 1,2-diazacyclobutane, 1,2-diazacyclopentane, 1,2-diazacyclohexane, or 1,2-diazacycloheptane ring.Y.sub.1 and Y.sub.2 are either hydrogen or OR.sub.11 but are not the same.R.sub.11 is hydrogen, alkanoyl of from one to ten carbon atoms, substituted alkanoyl of from two to ten carbon atoms, phenylcarbonyl, (substituted phenyl) carbonyl, heteroarylcarbonyl, phenylalkanoyl, (substituted phenyl) alkanoyl, or heteroarylalkanoyl.

Abstract: Monocyclic .beta.-lactam compounds represented by the formula ##STR1## wherein R.sub.1 is H, NH.sub.2, acylamino, C.sub.1 -C.sub.4 alkyl, etc.; R.sub.2 is e.g. C.sub.1 -C.sub.4 alkyl, hydroxyalkyl, aminoalkyl, carboxy, esterified carboxy, esterified carboxyalkyl, or carboxyalkyl; and R.sub.3 is hydrogen, benzyl, substituted benzyl, pivaloyl, --SO.sub.3 M, or --P(C.dbd.O)(OM')2; are obtained by the cyclization of an O-substituted hydroxamate of a .beta.-substituted alkylcarboxylic acid. For example, .alpha.-ethylmalic acid monobenzyl ester is reacted with O-benzylhydroxylamine to form the O-benzylhydroxamate of the free carboxy group, and the hydroxamate is cyclized with diethyl diazodicarboxylate and triphenylphosphine to form the .beta.-lactam of the above formula wherein R.sub.1 is ethyl, R.sub.2 is benzyloxycarbonyl and R.sub.3 is benzyl. The .beta.-lactam compounds are useful intermediates for preparing .beta.-lactamase inhibitors and monocyclic .beta.-lactam antibiotics and, when R.sub.3 is --SO.sub.

Abstract: Compounds of formula (I), which are useful as antihypercholesterolemic agents, are disclosed.

Abstract: The crystalline anhydrous form of [3S-[3.alpha.(Z), 4.beta.]]-3-[[(2-amino-4-thiazolyl) [(1-carboxy-1-methylethoxy)imino]acetyl]amino]-4-methyl-2-oxo-1-azetidines ulfonic acid is prepared.

Abstract: Antibiotic activity is exhibited by .beta.-lactams having an ##STR1## substituent (and analogs thereof) in the 1-position and an acylamino substituent in the 3-position.

Abstract: Gel-free concentrated aqueous formulations of vancomycin hydrochloride are provided which comprise the antibiotic salt at a concentration between about 12% and about 50% w/v and a gel-inhibiting compound, e.g., ethanol, at a concentration between about 1% and about 20% v/v. The gel-free formulations are especially useful in a freeze-drying process for preparing vancomycin hydrochloride as a dry flowable powder in bulk or in unit-dosage form.

Abstract: An antimicrobially active compound of the formula ##STR1## and pharmaceutically acceptable salts thereof: wherein R.sub.1 is hydrogen, --OCH.sub.3, or --NH--CHO; R.sub.2 is an acyl group derived from a carboxylic acid; R.sub.3 is selected from the group consisting of --CH.sub.2 --, --CH.sub.2 CH.sub.2 --, --CH.sub.2 CH.sub.2 CH.sub.2 --, and --CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.2 -- and when X is NL.sub.2 L.sub.3 then --CH.sub.2 CH.sub.2 --, --CH.sub.2 CH.sub.2 CH.sub.2 --, and --CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.2 -- are optionally substituted with one substituent selected from the group consisting of (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)carboxyalkyl, or (C.sub.1 -C.sub.4)alkylthio; X is --NL.sub.2 L.sub.3 or a pyrrole of the formula ##STR2## wherein L.sub.1 is hydrogen, --CO--O--CH.sub.2 --(C.sub.6 H.sub.5), or SO.sub.3 H; L.sub.2 is hydrogen, or SO.sub.3 H; and L.sub.3 is hydrogen, --CO--(C.sub.1 -C.sub.4)alkyl; --CH.dbd.NH, --C(NH.sub.2)=NH, --CO--O--CH.sub.2 --(C.sub.6 H.sub.5), --COH, or --SO.sub.

Abstract: This invention concerns 2-oxoazetidine analogs (monobactams) having antimicrobial activity, novel processes and novel intermediates useful to make monobactams. The compounds of this invention include compounds of the formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein: R.sub.1 is an acyl group derived from a carboxylic acid;A is either sulfo, phosphono or a trisubstituted silyl group substituted with (C.sub.1 -C.sub.4) alkyls or phenyl;R.sub.2 is selected from the group consisting of a. (C.sub.1 -C.sub.8) alkyl; b. (C.sub.2 -C.sub.8) alkenyl; c. (C.sub.3 -C.sub.8) alkynyl; d. (C.sub.3 -C.sub.8) cycloalkyl; e. (C.sub.6 -C.sub.8) aryl; f. (C.sub.6 -C.sub.12) aralkyl; g. heterocyclic radicals, where each member of (a) through (g) may be substituted by 1 to 4 substituents selected from group consisting of methoxy, hydroxy, halogen, nitro, and --N(R.sub.10)(R.sub.11) wherein R.sub.10 is hydrogen or alkyl (C.sub.1 -C.sub.4) and R.sub.11 is hydrogen, alkyl (C.sub.1 -C.sub.4) or alkoxy (C.sub.

Abstract: The crystalline delta(.delta.)-form of [3S-[3.alpha.(Z),-4.beta.]]-3-[[(2-amino-4-thiazolyl) [(1-carboxy-1-methylethoxy)imino]acetyl]amino]-4-methyl-2-oxo-1-azetidines ulfonic acid is prepared.

Abstract: Disclosed are compounds of the general formula: ##STR1## wherein R.sub.1 is amino, an acylated amino or a protected amino group, X is hydrogen or methoxy, and R' is hydrogen, R or R.sup.4 where R is an organic residue attached to the azetidine ring through a carbon atom therein and R.sub.4 is azido, a halogen, an amino group which may optionally be acylated or a group of the formula ##STR2## wherein R.sub.5 is an organic residue and n is 0, 1 or 2, and pharmaceutically acceptable salts and esters thereof.The compounds have antimicrobial and/or .beta.-lactamase-inhibitory activity and are of value as drugs for human beings and domesticated animals.

Abstract: Disclosed are compounds of the general formula: ##STR1## wherein R.sub.1 is amino, an acylated amino or a protected amino group, X is hydrogen or methoxy, and R' is hydrogen, R or R.sup.4 wherein R is an organic residue attached to the azetidine ring through a carbon atom therein and R.sub.4 is azido, a halogen, an amino group which may optionally be acylated or a group of the formula ##STR2## wherein R.sub.5 is an organic residue and n is 0, 1 or 2, and pharmeceutically acceptable salts and esters thereof.The compounds have antimicrobial and/or .beta.-lactamase-inhibitory activity and are of value as drugs for human beings and domesticated animals.

Abstract: Antimicrobial 2-oxo-1-azetidinesulphonic acids of the formula ##STR1## in which H.sub.2 N ##STR2## represents an amino-substituted thiazolyl group, R.sup.1 is lower alkyl which is substituted by carbamoyl, lower alkylsuphonyl, azido, piperidine-carbonyl, (hexahydro-1H-azepin-1-yl)carbonyl or lower alkynyl, and R.sup.2 is hydrogen or a lower organic group, typically, carbamoyloxymethyl.

Abstract: Disclosed herein is a process for preparing a compound having the formula ##STR1## which comprises sulfonating a compound having the formula ##STR2## with a complex having the formula ##STR3## and cyclizing the resulting compound having the formula ##STR4## by treatment with a base.

Abstract: A 2-azetidinone derivative having a group of the formula ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and each represents a hydrogen atom, alkyl, aryl or arylalkyl which may have a substituent at the 1-position and an amino group, at the 3-position, which may be acylated or protected, its salt or ester, and methods of producing the same, (1) a method comprising subjecting a 2-azetidinone derivative having a group of the formula ##STR2## wherein the symbols are as defined above at the 1-position and an amino group at the 3-position, its salt or ester to an acylation or protective-group introduction reaction, and (2) a method comprising reacting a 2-azetidinone derivative having a hydroxy group at the 1-position and an amino group, at the 3-position, which may be acylated or protected, or its salt with a compound of the formula ##STR3## wherein W is a halogen atom; other symbols are as defined above, its salt or ester.

Abstract: Disclosed are compounds of the general formula: ##STR1## wherein R.sub.1 is amino, an acylated amino or a protected amino group, X is hydrogen or methoxy, and R' is hydrogen, R or R.sup.4 wherein R is an organic residue attached to the azetidine ring through a carbon atom therein and R.sub.4 is azido, a halogen, an amino group which may optionally be acylated or a group of the formula ##STR2## wherein R.sub.5 is an organic residue and n is 0, 1 or 2, and pharmaceutically acceptable salts and esters thereof.The compounds have antimicrobial and/or .beta.-lactamase-inhibitory activity and are of value as drugs for human beings and domesticated animals.

Abstract: Antibacterial activity is exhibited by .beta.-lactams having a sulfonic acid salt substituent in the 1-position and an amino or acylamino substituent in the 3-position.

Abstract: The invention encompasses a process for stereoselective carbon-carbon bond formation at C-4 position of a 3-(acylamino)azetidinone. The process is carried out under free radical conditions using a (2-substituted or unsubstituted allyl)tin reagent. Also encompassed by the invention are certain 4-(substituted selenyl)azetidinone starting materials and the corresponding 4-(2'-substituted or unsubstituted allyl)-azetidinone products.

Abstract: Novel 1-sulfo-2-oxoazetidine derivatives and their production and use.These 1-sulfo-2-oxoazetidine derivatives exhibit excellent antimicrobial activity against gram-positive and gram-negative bacteria, and .beta.-lactamase inhibitory activity, thus being of value as a prophylactic or therapeutic agent for infectious diseases in mammals.

Abstract: A process for 4-halomethylazetidin-2-ones is provided which comprises mixing in an inert solvent a positive halogen reagent in the presence of a weak base with a .beta.,.gamma.-unsaturated O-acylhydroxamate of the formula ##STR1## wherein R is protected amino, lower alkyl or phenyl substituted lower alkyl, R.sub.2 is a substituent such as lower alkyl which may be substituted by formyl, hydroxy, halogen, etc., and R.sub.1 is alkoxy, benzyloxy, etc. When R is a protected amino group, the process provides cis-4-halomethylazetidin-2-ones, while when R is alkyl or phenylalkyl, the trans isomer is obtained. The 4-halomethylazetidinones are useful intermediates for known antibiotic compounds.

Abstract: An improved process for the manufacture of herbicidal 2-[(2-chlorophenyl)methyl]-4,4-dimethyl-3-isoxazolidinone by cyclizing 3-chloro-N-hydroxy-2,2-dimethylpropanamide with an alkaline or alkaline earth hydroxide at a pH of 7.5 to 9.5, benzylating the resulting 4,4-dimethyl-3-isoxazolidinone, eliminating by-product 1-[(2-chlorophenyl)methoxy]-3,3-dimethyl-2-azetidinone by contacting the product mixture with anhydrous hydrogen chloride, and further benzylating free isoxazolidinone with base.

Abstract: .beta.-Lactams having a sulfonic acid salt substituent in the 1-position, an acylamino substituent in the 3-position and an --NR.sub.2 R.sub.3 substituent in the 4-position wherein R.sub.2 and R.sub.3 are the same or different and each is ##STR1## or R.sub.2 and R.sub.3 together with the nitrogen atom to which they are attached are ##STR2## R.sub.4 is alkyl, aryl or arylalkyl; and R.sub.5 and R.sub.6 are the same or different and each is hydrogen, halogen, alkyl, alkoxy, alkylthio, alkoxycarbonyl, carboxyl or a carboxyl salt; have antibacterial activity.

Abstract: Novel 2-azetidinones of the formula ##STR1## wherein R is alkyl of 1 to 4 carbon atoms, R.sub.1 is selected from the group consisting of hydrogen, --OH, protected hydroxy and --OCH.sub.2 --COOR', R' is selected from the group consisting of hydrogen and alkyl of 1 to 4 carbon atoms and R.sub.2 is selected from the group consisting of alkyl of 1 to 4 carbon atoms and hydroxyl protective group and a novel process and novel intermediates for their preparation and a process for the preparation of compounds of the formula ##STR2## wherein R has the above definition, R'd is selected from the group consisting of hydrogen, --OH and protected hydroxyl and R.sub.3 is selected from the group consisting of hydrogen and R.sub.3 ', R.sub.3 ' is amino protective group which are useful intermediates.

Abstract: This invention provides novel antibacterial beta-lactams of the formula: ##STR1## in which R is alkyl of 1 to 6 carbon atoms, carboxyalkyl of 2 to 6 carbon atoms or alkoxycarbonylalkyl wherein the alkyl and alkoxy moieties contain, independently, 1 to 6 carbon atoms;R.sup.1 is alkylideneamino of 2 to 6 carbon atoms, alkanoylamino of 2 to 6 carbon atoms, carboxyalkylideneamino of 2 to 6 carbon atoms, alkylsulfonylamino of 1 to 6 carbon atoms, alkoxycarbonylalkylsulfonylamino of 3 to 13 carbon atoms, or N,N-cyclodialkanoylamino of 4 to 6 carbon atoms;or a pharmaceutically acceptable salt thereof.

Abstract: A compund having the formula ##STR1## can be prepared by coupling a compound having the formula ##STR2## or a salt thereof, with a compound having the formula ##STR3## to yield a compound having the formula ##STR4## and oxidizing that compound to yield the desired compound; wherein R is hydrogen or an amino protecting group;R.sub.1 is hydrogen, methly or ethyl;M.sup..sym. is an inorganic cation or a substituted ammonium ion; andM.sub.1.sup..sym. is hydrogen, an organic cation, or a substituted ammonium ion.

Abstract: Disclosed herein is a process for preparing a compound having the formula ##STR1## which comprises sulfonating a compound having the formula ##STR2## with a complex having the formula ##STR3## and cyclizing the resulting compound having the formula ##STR4## by treatment with a base.

Abstract: Antibacterial activity is exhibited by monocyclic .beta.-lactam antibiotics having in the 1-position an --O--SO.sub.3 H activating group and in the 3-position an acylamino group of the formula ##STR1## wherein R.sub.3 and R.sub.4 are each independently hydrogen or alkyl.

Abstract: 4-Cyano-2-azetidinone derivatives represented by the formula ##STR1## wherein R.sup.1 is an amino group which may be acylated or protected, X is a hydrogen atom or a methoxy group and W is a hydrogen atom or a sulfo group, and methods of producing the same, for example, as represented by ##STR2## wherein R.sup.2 is an acylated or protected amino group, Y is a halogen atom or a group having the formula --OCOR.sup.3, --SCOR.sup.3 or --S(O).sub.n --R.sup.3 (R.sup.3 being a hydrocarbyl group and n an integer 1 or 2), R.sup.4 is an amino group which may be acylated or protected and X is as defined above. Compounds [I] are useful as advantageous intermediates for the synthesis of optically active 4-substituted-2-azetidinone derivatives, and, when W=SO.sub.3 H, [I] are also useful as antimicrobial agents and as beta-lactamase inhibitors.

Abstract: Antimicrobial activity is exhibited by .beta.-lactams having a ##STR1## substituent in the 1-position and an acylamino substituent in the 3-position, or a pharmaceutically acceptable salt thereof; wherein Y is oxygen or sulfur and R.sub.5 is hydroxyl, alkyl, substituted alkyl, phenyl, substituted phenyl, alkoxy, alkylthio, (substituted alkyl)oxy, (substituted alkyl)thio, phenyloxy, phenylthio, (substituted phenyl)oxy or (substituted phenyl)thio.

Abstract: New substituted azetidinones are found to be potent elastase inhibitors and thereby useful anti-inflammatory/antidegenerative agents.

Abstract: A monocyclic .beta.-lactam antibiotic having a formamido substitutent at the 3S-position, including compounds of the formula (I): ##STR1## and salts thereof wherein R is --SO.sub.3 H; --PO(OH)Y wherein Y is C.sub.1-6 alkoxy, hydroxy, aryloxy, C.sub.1-6 alkyl or aryl; ##STR2## wherein Z represents C.sub.1-6 alkyl or aryl; ##STR3## wherein Z.sup.1 and Z.sup.2 may be the same or different and each represents hydrogen, C.sub.1-6 alkyl, aryl, amino or C.sub.1-6 alkoxy, or Z.sup.1 and Z.sup.2 together form the residue of a heterocyclic ring; --OSO.sub.3 H; or ##STR4## where X is hydrogen or hydroxy; R.sup.1 is an amino, protected amino or carboxylic acylamino group, and R.sup.2 and R.sup.3 are independently selected from hydrogen or a hydrocarbon group of 1 to 18 carbon atoms.

Abstract: The presence of a copper salt during the oximation of a .beta.-lactam containing compound having glyoxylamino substituents of the formula ##STR1## by reaction with an aminooxy compound having the formulaH.sub.2 N--O--R.sub.a,or a salt or ester thereof, results in a product wherein the ratio of syn isomer to anti isomer is increased.

Abstract: Disclosed are compounds of the general formula: ##STR1## wherein R.sub.1 is amino, an acylated amino or a protected amino group, X is hydrogen or methoxy, and R' is hydrogen, R or R.sup.4 wherein R is an organic residue attached to the azetidine ring through a carbon atom therein and R.sub.4 is azido, a halogen, an amino group which may optionally be acylated or a group of the formula --OR.sub.5, ##STR2## or --S--S--R.sub.5 wherein R.sub.5 is an organic residue and n is 0, 1 or 2, and pharmaceutically acceptable salts and esters thereof.The compounds have antimicrobial and/or .beta.-lactamase-inhibitory activity and are of value as drugs for human beings and domesticated animals.

Abstract: Process for N-acyloxy or sulfooxy 2-azetidinones comprising O-acylation of a .beta.-hydroxy or .beta.-halo hydroxamic acid, and cyclizing the O-acylhydroxamate with TPP-CCl.sub.4 -TEA or with TPP-dialkylazodicarboxylate to the N-acyloxy-2-azetidinone. Solvolysis of the acyl group provides an N-hydroxy-2-azetidinone. e.g., N-Cbz-L-serine is converted to the O-acetyl hydroxamate, cyclized and solvolyzed to N-hydroxy-3-(Cbz-amino)-2-azetidinone. The N-hydroxy-2-azetidinones are useful intermediates to monocyclic .beta.-lactam antibiotics and .beta.-lactamase inhibitors.

Abstract: Compounds of the formula ##STR1## are useful as intermediates in preparing 1-sulfo-2-oxoazetidine compounds having the carbamoyloxymethyl group at the 4-position. The final product compounds have antimicrobial and/or .beta.-lactamase-inhibitory activity and are of value as drugs for human beings and domesticated animals.

Abstract: Antibacterial activity is exhibited by .beta.-lactams having a 3-acylamino substituent and in the 1-position a substituent having the formula ##STR1## wherein R.sub.5 and R.sub.6 are the same or different and each is hydrogen, alkyl, alkenyl, alkynyl, phenyl, substituted phenyl, cycloalkyl or a 4,5,6 or 7-membered heterocycle, or R.sub.5 and R.sub.6 together with the carbon atom to which they are attached are cycloalkyl or a 4,5,6 or 7-membered heterocycle, or one of R.sub.5 and R.sub.6 is hydrogen and the other is azido, halomethyl, dihalomethyl, trihalomethyl, alkoxycarbonyl, alkenyl, alkynyl, 2-phenylethenyl, 2-phenylethynyl, carboxyl, --CH.sub.2 X.sub.1, --S--X.sub.2, --O--X.sub.2, or ##STR2## R.sub.7 is hydrogen, alkyl, substituted alkyl, phenyl, substituted phenyl, 1-(ethoxycarbonyloxy)ethyl, 1,3-dihydro-3-oxo-1-isobenzofuranyl, ##STR3## wherein R' is hydrogen or alkyl, R" is alkyl or phenyl, R"' is hydrogen, methyl or phenyl, and R.sup.iv is hydrogen or together with R"' is --(CH.sub.2).sub.

Abstract: Disclosed are compounds of the general formula: ##STR1## wherein R.sub.1 is amino, an acylated amino or a protected amino group, X is hydrogen or methoxy, and R' is hydrogen, R or R.sup.4 wherein R is an organic residue attached to the azetidine ring through a carbon atom therein and R.sub.4 is azido, a halogen, an amino group which may optionally be acylated or a group of the formula --OR.sub.5, ##STR2## or --S--S--R.sub.5 wherein R.sub.5 is an organic residue and n is 0, 1 or 2, and pharmaceutically acceptable salts and esters thereof.The compounds have antimicrobial and/or .beta.-lactamase-inhibitory activity and are of value as drugs for human beings and domesticated animals.

Abstract: Amino-beta-lactamic acid salts, having the formula: ##STR1## wherein: (X-Y) may form a system having from 1 to 3 carbon atoms, with or without double bond, (a) closed, in which: X is an atom selected from among carbon, oxygen, nitrogen and sulphur; Y is methylene; Z is a carboxy, sulphonic or phosphonic group (b) open, which may comprise a double bond, in which: X is an atom of hydrogen or a methyl, hydroxymethyl or thiol group, Y is an acid radical chosen from the group formed by sulphonic, phosphonic and sulphoamidic acid; Z is missing. R is an atom or hydrogen, or a methoxyl or ethoxyl group. R.sub.1 is, when present, methyl, acetoxymethyl, acylthiomethyl, such as acetyl and benzoyl derivatives, methoxy, chlorine, carbamoyloxymethyl, azido, azidomethyl (alpha, beta)-thioethylamine or a thiomethyl-heterocyclic derivative of the thiazole, thiadiazole, triazole, tetrazole, oxazole, oxadiazole, pyrimidine and imidazole nuclei. R.sub.2 is an atom of hydrogen or a methyl, ethyl, benzyl or phenyl group.

Abstract: A class of ortho-sulfamoyl sulfonamides are useful as pre-emergent or post-emergent herbicides and plant growth regulants.

Abstract: Antibacterial activity is exhibited by 2-azetidinones activated in the 1-position with an --SO.sub.

Abstract: A monocyclic .beta.-lactam antibiotic having a formamido substituent at the 3S-position, including compounds of the formula (I): ##STR1## and salts thereof wherein R is --SO.sub.3 H; --PO(OH)Y wherein Y is C.sub.1-6 alkoxy, hydroxy, aryloxy, C.sub.1-6 alkyl or aryl; ##STR2## wherein Z represents C.sub.1-6 alkyl or aryl; ##STR3## wherein Z.sup.1 and Z.sup.2 may be the same or different and each represents hydrogen, C.sub.1-6 alkyl, aryl, amino or C.sub.1-6 alkoxy, or Z.sup.1 and Z.sup.2 together form the residue of a heterocyclic ring; --OSO.sub.3 H; or ##STR4## where X is hydrogen or hydroxy; R.sup.1 is an amino, protected amino or carboxylic acylamino group, and R.sup.2 and R.sup.3 are independently selected from hydrogen or a hydrocarbon group of 1 to 18 carbon atoms.

Abstract: Antibacterial activity is exhibited by 2-azetidinones activated in the 1-position with an --SO.sub.3 H group and having in the 3-position an acylamino group of the formula ##STR1## wherein X is --(CH.sub.2).sub.

Abstract: Pharmaceutically acceptable salts of [3S(Z)]-2-[[[1-(2-amino-4-thiazolyl)-2-[[2,2-dimethyl-4-oxo-1-(sulfooxy)-3 -azetidinyl]amino]-2-oxoethylidene]amino]oxy] acetic acid and a process useful in the preparation of such salts are disclosed herein.